Zhejiang East Asia Pharmaceutical Co., Ltd.SSE: 605177

Earnings Preannouncement for 2025

Jan 23, 2026 · Issued by Zhejiang East Asia Pharmaceutical Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Jan 23, 2026

On 6ix: 6ix.com/news/earnings-preannouncement-for-2025-250

Earnings Preannouncement for 2025

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Zhejiang East Asia Pharmaceutical Co., Ltd. on 6ix

Earlier from Zhejiang East Asia Pharmaceutical

Indicative Announcement on Expected Loss in Performance for 2025Jan 15
Indicative Announcement on Expected Satisfaction of Conversion Price Correction Conditions for ""East-Asia Convertible Bonds"Dec 31, 2025
Announcement on Resolutions of the 13th Meeting of the 4th Board of DirectorsDec 26, 2025
Announcement on Using Temporarily Idle Self-owned Funds for Entrusted Wealth ManagementDec 10, 2025
Announcement on Convening Performance Briefing for Q3 2025Nov 12, 2025

Later from Zhejiang East Asia Pharmaceutical

Announcement on Resolutions of the 14th Meeting of the 4th Board of DirectorsFeb 7
Announcement on Obtaining Drug Registration Certificate for Fumonol Vonol TabletsMar 5
Announcement on Obtaining Drug Registration Certificate for Saxagliptin and Metformin Hydrochloride Extended-Release TabletsMar 17
Announcement on Completing the Repurchase and Cancellation of Some Restricted Stocks without Adjusting Conversion Price of Convertible BondsMar 27
Announcement on Conversion Result of Convertible Bonds and Share ChangesApr 3

All Zhejiang East Asia Pharmaceutical news releases

Follow Zhejiang East Asia Pharmaceutical into a list and get an email when it puts out news.

Follow Zhejiang East Asia Pharmaceutical